MCID: CRV002
MIFTS: 45

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 11 14 33
Carcinoma in Situ of Uterine Cervix 11 71
Cervical Intraepithelial Neoplasia 43 71
Carcinoma in Situ of Cervix 11 33
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 11
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 71
Squamous Intraepithelial Neoplasia, Grade Iii 11
Cin Iii - Carcinoma in Situ of Cervix 11
Severe Dysplasia of the Cervix Uteri 11
Cin Iii - Severe Dyskaryosis 11
Carcinoma of Cervix Stage 0 11
Severe Dysplasia of Cervix 11
Cervix Ca in Situ 11
Cin Iii 11

Classifications:



External Ids:

Disease Ontology 11 DOID:8991
ICD9CM 34 233.1
MeSH 43 D018290
SNOMED-CT 68 92564006
ICD10 31 D06 D06.9
UMLS 71 C0206708 C0851140 C2987516

Summaries for Cervix Uteri Carcinoma in Situ

Disease Ontology: 11 An uterus carcinoma in situ that is located in the uterine cervix.

MalaCards based summary: Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and human papillomavirus infectious disease. An important gene associated with Cervix Uteri Carcinoma in Situ is CADM1 (Cell Adhesion Molecule 1), and among its related pathways/superpathways are 22q11.2 copy number variation syndrome and TP53 network. The drugs Aluminum hydroxide and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include uterine cervix, cervix and uterus, and related phenotype is homeostasis/metabolism.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases in the Rare Cancer of Cervix Uteri family:

Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 cervicitis 31.2 ZNF582 SERPIND1 GP6 GP5 CDKN2A
2 human papillomavirus infectious disease 31.2 TP53 GP5 FHIT CDKN2A
3 cervical intraepithelial neoplasia 31.1 KRT17 FHIT CDKN2A
4 vulva cancer 30.7 ZNF582 TP53 GP5 CDKN2A
5 cervical adenocarcinoma 30.7 TP53 MAPK8IP1 INSM1 CDKN2A
6 anus cancer 30.6 ZNF582 TP53 GP6 GP5 CDKN2A
7 cervix carcinoma 30.5 TP53 PTPRN MAPK8IP1 INSM1 GP5 CDKN2A
8 adenosquamous carcinoma 30.5 PTPRN MAPK8IP1 INSM1 FHIT
9 cervical carcinosarcoma 30.4 MAPK8IP1 GP5
10 cervical incompetence 30.4 PTPRN MAPK8IP1 INSM1
11 suppressor of tumorigenicity 3 30.4 TP53 FHIT CDKN2A
12 keratinizing squamous cell carcinoma 30.3 TP53 CDKN2A
13 cervical squamous cell carcinoma 30.3 TP53 KRT17 FHIT CDKN2A
14 oropharynx cancer 30.3 TP53 GP5 CDKN2A
15 chronic cervicitis 30.2 ZNF582 TP53 SERPIND1 PAX1 INSM1 GP6
16 epidermodysplasia verruciformis 1 30.2 TP53 GP6 GP5 CDKN2A
17 anus disease 30.2 ZNF582 TP53 GP5 CDKN2A
18 endocervical adenocarcinoma 30.2 TP53 MAPK8IP1 INSM1 CDKN2A
19 vaginal cancer 30.1 TP53 MAPK8IP1 INSM1 GP5 CDKN2A
20 anogenital venereal wart 30.1 TP53 GP6 GP5 CDKN2A
21 vulva squamous cell carcinoma 30.0 ZNF582 TP53 GP5 CDKN2A
22 cervical cancer 29.9 TP53 RUBCNL FHIT CDKN2A CADM1
23 adenocarcinoma in situ 29.8 TP53 PTPRN MAPK8IP1 INSM1 GP5 CDKN2A
24 common cold 10.8
25 chlamydia 10.8
26 viral infectious disease 10.7
27 bacterial vaginosis 10.6
28 vaginal discharge 10.6
29 rhabdomyosarcoma 2 10.5
30 retinoblastoma 10.5
31 vaginitis 10.5
32 hypoascorbemia 10.5
33 human immunodeficiency virus type 1 10.5
34 oculodentodigital dysplasia 10.4
35 preterm premature rupture of the membranes 10.4
36 47 xxx syndrome 10.4
37 ceroid lipofuscinosis, neuronal, 5 10.4
38 herpes simplex 10.4
39 factor vii deficiency 10.4
40 progressive non-infectious anterior vertebral fusion 10.4
41 polyploidy 10.4
42 early invasive cervical adenocarcinoma 10.3 INSM1 CDKN2A
43 photoparoxysmal response 1 10.3
44 ectopic pregnancy 10.3
45 turner syndrome 10.3
46 syphilis 10.3
47 48,xyyy 10.3
48 cervical adenoid basal carcinoma 10.3 MAPK8IP1 KRT17
49 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.3 TP53 CDKN2A
50 endometrial squamous cell carcinoma 10.3 TP53 CDKN2A

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Adenomyosis Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

MGI Mouse Phenotypes related to Cervix Uteri Carcinoma in Situ:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.47 CDKN2A FHIT GP5 GP6 INSM1 KRT17

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
3
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
4 Monophosphoryl lipid A Phase 4
5 Epinephryl borate Phase 4
6 Neurotransmitter Agents Phase 4
7 Bronchodilator Agents Phase 4
8 Adrenergic beta-Agonists Phase 4
9 Adrenergic alpha-Agonists Phase 4
10 Adrenergic Agonists Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Adrenergic Agents Phase 4
13 Vasoconstrictor Agents Phase 4
14 Anesthetics, Local Phase 4
15 Respiratory System Agents Phase 4
16 Mydriatics Phase 4
17 Sympathomimetics Phase 4
18 Vaccines Phase 4
19
Fluorouracil Approved Phase 3 51-21-8 3385
20
Aluminum sulfate Approved Phase 3 10043-01-3
21
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
22
Eugenol Approved Phase 3 97-53-0 3314
23
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
24
Acetic acid Approved Phase 3 64-19-7 176
25
Fenretinide Investigational Phase 3 65646-68-6 5288209
26
3,3'-diindolylmethane Investigational Phase 3 1968-05-4 3071
27
Zuretinol acetate Investigational Phase 3 127-47-9, 29584-22-3 10245972
28 Antimetabolites Phase 3
29 Immunosuppressive Agents Phase 3
30 Anesthetics Phase 3
31 Antiviral Agents Phase 3
32 Retinamide Phase 3
33 Protective Agents Phase 3
34 Immunoglobulins Phase 3
35 Antibodies Phase 3
36 Hemostatics Phase 3
37 Olive Phase 3
38 Anti-Arrhythmia Agents Phase 3
39 Sodium Channel Blockers Phase 3
40 Diuretics, Potassium Sparing Phase 3
41 Adjuvants, Immunologic Phase 3
42 interferons Phase 3
43 Immunologic Factors Phase 3
44 Raspberry Approved Phase 2
45
Aluminium phosphate Approved, Investigational Phase 2 7784-30-7
46
Eflornithine Approved, Withdrawn Phase 2 70052-12-9 3009
47
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
48
Masoprocol Approved, Investigational Phase 1, Phase 2 500-38-9, 27686-84-6 71398
49
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
50
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230

Interventional clinical trials:

(show top 50) (show all 302)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
4 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Completed NCT03105856 Phase 4
5 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
6 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Completed NCT03629886 Phase 4
7 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
8 A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years Completed NCT05426148 Phase 4
9 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Active, not recruiting NCT02149030 Phase 4
11 Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV Not yet recruiting NCT05266898 Phase 4
12 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
13 DNA Methylation Testing for the Screening of Uterine Cervical Lesion: A Multicenter, Prospective Cohort Study Unknown status NCT04646954 Phase 3
14 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
15 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Unknown status NCT03366493 Phase 3
16 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
17 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
18 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
19 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
20 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
21 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
22 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
23 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
24 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
25 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
26 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
27 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
28 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
29 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
30 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
31 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
32 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
33 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Completed NCT03721978 Phase 3
34 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
35 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
36 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
37 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Completed NCT03185013 Phase 3
38 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene
39 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
40 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
41 A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) Active, not recruiting NCT04484415 Phase 3
42 A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years Active, not recruiting NCT04537156 Phase 3
43 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
44 A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer. Not yet recruiting NCT03848039 Phase 3 Placebo
45 A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia Terminated NCT00529464 Phase 3
46 ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial Terminated NCT01283763 Phase 3 Topical Imiquimod
47 TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial. Terminated NCT02329171 Phase 3 Imiquimod
48 A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Unknown status NCT03745846 Phase 2
49 A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) Unknown status NCT03274206 Phase 2 Placebo
50 A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3) Unknown status NCT02596243 Phase 2

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

Organs/tissues related to Cervix Uteri Carcinoma in Situ:

FMA: Uterine Cervix
MalaCards : Cervix, Uterus, Lymph Node, Nk Cells, Skin, Liver, T Cells

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 1045)
# Title Authors PMID Year
1
COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system: A hypothesis. 62
36399874 2022
2
The Effect of Local Photodynamic Therapy with 5-aminolevulinic Acid in Treating Different Grades of Cervical Intraepithelial Neoplasia. 62
36368451 2022
3
HPV-genotyping versus conventional cervical cytology as a screening method to detect dysplastic cervical epithelial changes. 62
36280748 2022
4
Analysis of the Results of Severe Intraepithelial Squamous Cell Lesions and Preinvasive Cervical Cancer Phototheranostics in Women of Reproductive Age. 62
36289783 2022
5
Concordance Rate of Colposcopy in Detecting Cervical Intraepithelial Lesions. 62
36292125 2022
6
FT-IR combined with PSO-CNN algorithm for rapid screening of cervical tumors. 62
35868522 2022
7
Fermented Mangosteen (Garcinia mangostana L.) Supplementation in the Prevention of HPV-Induced Cervical Cancer: From Mechanisms to Clinical Outcomes. 62
36230630 2022
8
Immunohistochemical Study of p16INK4A, MIB-1 and CK17 in Pre-neoplastic and Neoplastic Epithelial Lesions of Cervix. 62
36448068 2022
9
Ocular Surface Squamous Neoplasia: A 12-Month Prospective Evaluation of Incidence in Waikato, New Zealand. 62
35997381 2022
10
Evaluation of P16/Ki67 (CINtecPlus) and L1-capsid compared with HPV-genotyping in cervical cytology in women ≥35 years old focusing on patients with atypical squamous cells of undetermined significance. 62
35720497 2022
11
Clinical Outcomes Associated with Endocervical Glandular Involvement in Patients with Cervical Intraepithelial Neoplasia III. 62
35683385 2022
12
A Study of Cytokeratin-7 Expression and Clinicopathological Correlation in Dysplasia and Squamous Cell Carcinoma of the Cervix. 62
35345360 2022
13
Anal intraepithelial neoplasia screening in patients with human immunodeficiency virus infection. 62
35285660 2022
14
Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia. 62
34739585 2022
15
Pilot Study on the Effect of a Single Topical Application of Trichloroacetic Acid 85% on Normal Cervical Tissue. 62
35668953 2022
16
Predictive Value of HPV E6/E7 mRNA Detection on the Outcome of Cervical LSIL. 62
35978997 2022
17
Cervical Pre-cancers: Biopsy and Immunohistochemistry. 62
35928531 2022
18
Diagnosis of Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma by Cervical Biopsy under Colposcopy and Analysis of Factors Influencing. 62
35941961 2022
19
Phototheranostics of Cervical Neoplasms with Chlorin e6 Photosensitizer. 62
35008375 2022
20
Raman spectroscopic study of cervical precancerous lesions and cervical cancer. 62
33404885 2021
21
Prognostic impact of human papillomavirus infection on cervical dysplasia, cancer, and patient survival in Saudi Arabia: A 10-year retrospective analysis. 62
34873934 2021
22
Coexistence of cervical endometriosis with premalignant and malignant gynecological pathologies: report on a series of 27 cases. 62
34696701 2021
23
Preliminary study of the use of E6/E7mRNA detection in screening and triage management of HR-HPV infection during pregnancy. 62
34733980 2021
24
Pathways of IFN-alpha Activation in Patients with Cervical Intraepithelial Neoplasia (CIN). 62
34670303 2021
25
Clinical value of traditional laparotomy, extensive vaginal hysterectomy, and laparoscope-assisted vaginal hysterectomy in the treatment of patients with cervical intraepithelial neoplasia III. 62
35116556 2021
26
HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1. 62
33631046 2021
27
Detection of HPV E6/E7 mRNA in the diagnosis of cervical cancer and precancerous lesions after kidney transplantation. 62
34306499 2021
28
The Help of HPV Integration Testing to Avoid the Misdiagnosis of a Patient with Stage Ia1 Cervical Cancer: A Case Report and Literature Review. 62
34819743 2021
29
Correlation between multi-type human papillomavirus infections and viral loads and the cervical pathological grade. 62
33020921 2021
30
IMMUNOHISTOCHEMICAL FEATURES OF THE EXPRESSION OF HUMAN PAPILLOMA VIRUS TYPE 16 IN PLEOMORPHIC ADENOMAS OF SALIVARY GLAND. 62
33851578 2021
31
Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 (PDCD1) rs36084323 A Allele in a Dominant Model. 62
34290992 2021
32
Occult vaginal cancer recurrence after hysterectomy: a case report and literature review. 62
33275476 2020
33
Co-infection between genotypes of the human papillomavirus and Chlamydia trachomatis in Mexican women. 62
32998641 2020
34
Cytological, Colposcopic and Pathohistological Correlation of HSIL and ASC H Findings. 62
33424094 2020
35
A Study of Matrix Metalloproteinase-2 and Interleukin-18 in Preinvasive and Invasive Lesions of Cancer Cervix. 62
33767565 2020
36
Ichthyosis uteri with dysplasia - A case report. 62
33154324 2020
37
A Cervical Smear Scare due to Monsel's Solution: A Case Report. 62
34434339 2020
38
Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening. 62
32680634 2020
39
Cisplatin treatment modulates Annexin A1 and inhibitor of differentiation to DNA 1 expression in cervical cancer cells. 62
32768930 2020
40
HIF-1α, HIF-2α, and ProExC: diagnostic or prognostic relevance in conjunctival intraepithelial neoplasia? 62
32458097 2020
41
The Burden of Cervical Cancer in Korea: A Population-Based Study. 62
32872616 2020
42
Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development. 62
32724435 2020
43
Study on the correlation between hTREC and HPV load and cervical CINI/II/III lesions and cervical cancer. 62
32100923 2020
44
Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation. 62
32157438 2020
45
Expression level of miRNA-210-3p in cervical cancer and its prognostic potential. 62
32633346 2020
46
Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. 62
32517663 2020
47
Relevance research between the expression of p16INK4a , Notch1, and hTERC genes: The development of HPV16-positive cervical cancer. 62
31976596 2020
48
p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening. 62
32410798 2020
49
Cervical carcinoma risk associate with genetic polymorphisms of NEIL2 gene in Chinese population and its significance as predictive biomarker. 62
32198476 2020
50
CIN III and cervical SCC with negative oncogenic HPV PCR: A case series. 62
31724153 2020

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

Pathways related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.45 TP53 SERPIND1 GP5
2
Show member pathways
10.26 TP53 CDKN2A
3 9.85 TP53 CDKN2A

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.65 TP53 MAL LGALS7B LGALS7 FHIT CDKN2A
2 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.55 LGALS7B LGALS7 CADM1
3 hemostasis GO:0007599 8.8 SERPIND1 GP6 GP5

Molecular functions related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 galactoside binding GO:0016936 8.8 LGALS7B LGALS7

Sources for Cervix Uteri Carcinoma in Situ

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....